Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Research and Innovation Action · Running

GENIAL Understanding Gene ENvironment Interaction in ALcohol-related hepatocellular carcinoma

Coordinator
Universite Libre De Bruxelles, Belgium
Runs
1 January 2023 to 31 December 2027
Status
Running
EU funding
€12.0m
Total cost
€12.0m
Partners
15 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101096312

What the project is doing

In the project's own words, from its summary on CORDIS.

Alcohol-related hepatocellular carcinoma (ALD-HCC) is, in Europe, the leading cause of liver cancer (2nd most common cause of cancer-related death worldwide, affecting both men and women). ALD-HCC has a median 5-year survival rate of 15%. Yet, the prognosis is driven by the tumour stage, with curative options providing a 5-year survival exceeding 70% for early-stage HCC (<20% of cases). Therefore, interventions aiming to improve prevention and early detection are key.

ALD-HCC results from the interplay between environmental determinants and genetic variations. A comprehensive characterisation of environmental factors (e.g. diet, lifestyle) linked to ALD-HCC is still lacking. We recently performed the 1st genome-wide association study of ALD-HCC and identified predisposing genetic variations. However, their role on alcohol-related liver carcinogenesis needs clarification and the genetic architecture of ALD-HCC remains mostly unknown.

GENIAL brings together partners with unique expertise in clinical hepatology, single-cell and spatial multi-omics, artificial intelligence (AI) and communication and dissemination capacities. Our aim is to 1) portray genetic and environmental determinants promoting ALD-HCC; 2) evaluate how they interact at cellular level in human samples and preclinical models to get novel insights into liver carcinogenesis, and identify chemopreventive targets; and 3) assess how these determinants modulate the ALD-HCC risk in prospective cohorts of patients included in HCC surveillance programs.

Environmental factors will be comprehensively characterised in an ongoing clinical trial designed to evaluate alternative methods for early-stage HCC detection. Finally, AI models, reaching the minimal viable product stage by the end of GENIAL, will be used to integrate genetic and non-genetic information (including digital imaging) to develop novel cost-effective strategies towards prevention and early-stage detection of ALD-HCC in at-risk individuals.

This action is part of the Cancer Mission cluster of projects on ‘‘Understanding’.

Topics

Who is involved

OrganisationCityCountryRole
Universite Libre De BruxellesBruxellesBelgiumCoordinator
European Liver Patients AssociationBruxelles / BrusselBelgiumParticipant
Vib VzwZwijnaarde - GentBelgiumParticipant
European Association for the Studyof the LiverGeneveSwitzerlandAssociatedpartner
Technische Universitaet DresdenDresdenGermanyParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Epsa Innovation FranceIssy-Les-MoulineauxFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universite Paris 13VilletaneuseFranceParticipant
Universite Paris CiteParisFranceParticipant
Fondazione Irccs Ca' Granda - Ospedale Maggiore PoliclinicoMilanoItalyParticipant
Fondazione Irccs Ca' Granda - Ospedale Maggiore PoliclinicoMilanoItalyThird party
Universita Degli Studi Di MilanoMilanoItalyParticipant
Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez ChampalimaudLisboaPortugalParticipant
StratiPath ABSolnaSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI